Novo Nordisk's stock has dropped over 30% since mid-2024 amid ongoing downtrend. Investors are focusing on the upcoming Q2 earnings report, paying close attention to management's confidence in their transformation plans rather than short-term earnings beats. The rapid uptake of oral Wegovy is expanding Novo's market by attracting new GLP-1 patients without significantly impacting existing treatments. Potential regulatory filings, including in China and for the new drug CagriSema, could drive growth and improve valuation multiples in 2026 and 2027. Analyst Danil Sereda remains bullish on Novo Nordisk despite recent stock declines.
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, sup...
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
